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Resolution of inflammation has emerged as an active process in
immunobiology, with cells of the mononuclear phagocyte system
being critical in mediating efferocytosis and wound debridement
and bridging the gap between innate and adaptive immunity.
Here we investigated the roles of cytochrome P450 (CYP)-derived
epoxy-oxylipins in a well-characterized model of sterile resolving
peritonitis in the mouse. Epoxy-oxylipins were produced in a
biphasic manner during the peaks of acute (4 h) and resolution
phases (24–48 h) of the response. The epoxygenase inhibitor
SKF525A (epoxI) given at 24 h selectively inhibited arachidonic
acid- and linoleic acid-derived CYP450-epoxy-oxlipins and resulted
in a dramatic influx in monocytes. The epoxI-recruited monocytes
were strongly GR1+, Ly6chi, CCR2hi, CCL2hi, and CX3CR1lo. In addi-
tion, expression of F4/80 and the recruitment of T cells, B cells, and
dendritic cells were suppressed. sEH (Ephx2)−/− mice, which have
elevated epoxy-oxylipins, demonstrated opposing effects to epoxI-
treated mice: reduced Ly6chi monocytes and elevated F4/80hi macro-
phages and B, T, and dendritic cells. Ly6chi and Ly6clo monocytes,
resident macrophages, and recruited dendritic cells all showed a dra-
matic change in their resolution signature following in vivo epoxI
treatment. Markers of macrophage differentiation CD11b, MerTK,
and CD103 were reduced, and monocyte-derived macrophages
and resident macrophages ex vivo showed greatly impaired
phagocytosis of zymosan and efferocytosis of apoptotic thymo-
cytes following epoxI treatment. These findings demonstrate that
epoxy-oxylipins have a critical role in monocyte lineage recruit-
ment and activity to promote inflammatory resolution and repre-
sent a previously unidentified internal regulatory system governing
the establishment of adaptive immunity.
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Monocytes and monocyte-derived macrophages play a criti-cal role in chronic inflammation, in part via the production
and release of lipid mediators (1). One such lipid precursor, ara-
chidonic acid, is metabolized into families of biologically active me-
diators by the cyclooxygenase, lipoxygenase, and cytochrome P450
(CYP) pathways (2, 3). CYPs metabolize arachidonic acid by: (i) an
epoxygenase activity that catalyzes the conversion of arachidonic
acid to epoxyeicosatrienoic acids (EETs); (ii) a lipoxygenase-like
activity that metabolizes arachidonic acid to midchain hydrox-
yeicosatetraenoic acids (HETEs); and (iii) ω- and ω-1-hydroxylase
activity, which produces ω-terminal HETEs (3). In addition to
arachidonic acid, CYPs with epoxygenase activity can also
metabolize alternative polyunsaturated fatty acids such as lino-
leic acid and docosahexaenoic acid into a series of products
including epoxyoctadacamonoenoic acids (EpOMEs) and 19,20-
epoxydocosapentaenoic acid (EpDPE), respectively, whose func-
tions remain poorly understood (3–5).
The main polyunsaturated fatty acid-metabolizing CYPs belong
to the CYP2 family, in particular the CYP2J and CYP2C subfam-
ilies (3, 4, 6, 7). Moreover, these CYP-lipid–metabolizing enzymes
are the primary sources of eicosanoids in small blood vessels, the
kidney, liver, lung, intestines, heart, and pancreas (3, 7). In most
organs, EETs and related epoxygenase products are metabolically
unstable and are rapidly metabolized. The major pathway that
regulates EET metabolism is that catalyzed by epoxide hydrolases
(8), which convert EETs to less biologically active dihydroxyeicosa-
trienoic acids (DHETs) (9). EpOMEs similarly get converted into
dihydroxyoctadecenoic acids (DiHOMEs), whereas 19,20-EpDPE
gets converted into 19,20-dihydroxydocosapentaenoic acid (DiHDPA).
Elevating the levels of endogenous CYP products by disrupting
(knockout) or inhibiting soluble epoxide hydrolase (sEH) reduces
neointima formation (10), atherosclerosis, abdominal aortic aneurysm,
dyslipidemia (11), hypertension (12), and diabetes (13) in different
mouse models, all of which to some extent one could argue have a
degree of nonresolving inflammation.
Over the last 15 y there has been a vast increase in our knowledge
of fatty acid mediators that regulate inflammatory processes,
particularly newly identified mediators such as the resolvins that
mediate the resolution of inflammation (14–16). However, unlike
cyclooxygenase and lipoxygenase products, the roles of CYP450
pathways in chronic inflammation remain unclear. The arachidonic
acid products of the CYP epoxygenases, the EETs, can regulate
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vascular tone, smooth muscle cell mitogenesis, platelet aggregation,
steroidogenesis, and endothelial and vascular smooth muscle cell
activation (4, 5, 7, 17–19). We recently published that in human
monocytes and macrophages, epoxygenases and some of their ara-
chidonic acid products were antiinflammatory through their ability to
activate the peroxisome proliferator-activated receptor (PPAR), in
particular PPARα (20, 21). Overexpression of epoxygenase enzymes
CYP2J2 and CYP2C8 or genetic disruption of sEH (sEH−/−) inhibits
LPS-induced pulmonary inflammation (22, 23), and sEH−/−mice or
treatment with sEH inhibitors is highly effective against inflam-
matory and neuropathic pain (24–27).
Monocytes are heterogeneous in mice and in humans (28). In
mice, monocyte subsets can be divided based on the expression of
Ly6c, Gr1, CC-chemokine receptor 2 (CCR2), and CX3C-chemokine
receptor 1 (CX3CR1). Ly6chi monocytes are Gr1+, CCR2+,
and CX3CR1lo, whereas Ly6clo monocytes are Gr1−, CCR2−, and
CX3CR1hi (29, 30). Lipid mediators that regulate the recruitment
and phenotype of monocytes are poorly understood.
Herein, using a sterile model of inflammatory resolution dependent
on monocyte recruitment, we found that CYP-epoxygenase products
not only accumulate in a temporal manner with monocyte recruitment
but also limit proinflammatory monocyte recruitment and promote a
proresolution phenotype in cells of the monocyte lineage.
Results
CYP450-Derived Lipid Metabolites Form Part of the Coordinated
Eicosanoid Fatty Acid Metabolite Response in Acute Inflammation
and Resolution. The naive mouse peritoneal cavity contains high
levels of linoleic acid [9- and 13-hydroxy-octadecadienoic acid
(HODE)] and arachidonic acid (8-, 12-, and 15-HETE)-derived
lipoxygenase products as well as 9,10- and 12,13-DiHOME,
which are epoxide diols of the linoleic acid epoxygenase products
9,10-EpOME and 12,13-EpOME (Fig. 1). Cyclooxygenase
(COX), CYP450, 5-lipoxygenase (LO), and eicosapentaenoic
acid (EPA)/docosahexaenoic acid (DHA)-derived mediators,
including prostanoids, leukotrienes, EETs, and their metabolites,
Fig. 1. LC/MS/MS analysis of oxylipin-generating pathways in the mouse peritoneal cavity during acute inflammation and resolution initiated by zymosan A.
(A) Absolute levels of oxylipins determined in naive peritoneal cavity lavage fluid of male C57BL/6 mice. (B) Sum of oxylipin-generated COX, CYP450, CYP450-
lipoxygenase–like (CYP-L), or LO pathways using either arachidonic acid (AA), linoleic acid (LA), DHA, or EPA as a substrate in the naive peritoneal cavity.
(C ) Heatmap showing fold changes in oxylipin formation following zymosan A treatment (1 mg, i.p.) from 0 to 4 h (peak of acute inflammation), 24 h, and
48 h (resolution). (D and E ) Fold-normalized square root of oxylipins produced by COX-AA (prostanoids), CYP-AA (DHETs), CYP-L-AA (19- and 20-HETE),
CYP-DHA (19,20-EpDPE and 19,20-DiHDPA), CYP-EPA (17,18-DHEQ), and 5-LO-AA (5-HETE) pathways (D) and CYP-LA (EpOMEs and DiHOMEs), 8/12/15-LO
(8-, 12-, and 15-HETE), and LO-LA (HODEs) pathways (E ) in response to zymosan A over 48 h. Pathways in D and E represent two distinct responses to
challenge with zymosan A. Data represent the mean ± SEM from n = 4–8 mice per group.
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were found at much lower levels (Fig. 1). The liquid chromatog-
raphy/tandem mass spectrometry (LC/MS/MS) assay we used was
primarily designed to measure CYP450 and related products. We
do not currently measure some of the other newly characterized
lipid species known to regulate inflammatory resolution such as
the resolvins, but clearly enzymatic pathways and lipid precur-
sors for these pathways are all also present. During the acute
inflammatory response elicited by zymosan (4 h), there was the
expected burst of prostanoids, increases in 5-, 11-, 19-, and 20-
HETE, and also increases in the CYP450 epoxygenase-derived
oxylipins 5,6-, 8,9-, 11,12-, and 14,15-DHET and 17,18-dihydroxy-
EEQ (DHEQ) (Fig. 1 C and D and SI Appendix, Fig. S1). The
DHETs are the epoxide hydrolase diols of the P450 metabolites
and could readily be detected, whereas parental EETs were not
seen. The 15/12-lipoxygenase products initially found at high
levels in the naive cavity dropped dramatically during acute in-
flammation (9- and 13-HODE and 8-, 12-, and 15-HETE), with
only 9-HODE and 8-HETE returning to baseline levels over the
48-h time course (Fig. 1 C and E and SI Appendix). After acute
inflammation, which is driven primarily by polymorphonuclear
cells (PMNs), resolution begins and is associated with an accumu-
lation of proresolution monocytes peaking 24–48 h after the initial
inflammatory insult. After a drop at 24 h, this influx in monocytes
was associated with a second phase of epoxy-oxylipin production
of arachidonic acid (DHETs), linoleic acid (DiHOMEs), EPA
(17,18-DHEQ), and DHA (19,20-DiHDPA) epoxygenase products
(Fig. 2 A and B). Moreover, this phase was associated with the
biosynthesis of new lipid products, as the addition of a selective
epoxygenase inhibitor (epoxI; SKF525A; 30 mg/kg, i.p.) to zymosan-
treated mice from 24 h onward led to a selective and specific in-
hibition of arachidonic acid and linoleic acid epoxy-oxylipins (Fig.
2C). EpoxI had no significant effect on COX, LO, or CYP450-
lipoxygenase–like products (SI Appendix, Table S1), indicating
the epoxI used is highly selective for the CYP-epoxygenase
pathway.
We screened the mouse Cyp2 family to investigate which en-
zymes were present in the resolution-phase inflammatory cell
populations, and found Cyp2c44, Cyp2j5, Cyp2j6, Cyp2j9, and
Cyp2j13 epoxygenases along with Cyp2u1 (HETE and DHA
metabolism) and Cyp2s1 (xenobiotic and retinoic acid metabo-
lism) (Table 1 and SI Appendix, Fig. S2).
Epoxygenase Inhibition During Resolution Induces a Profound
Accumulation of Ly6chi Monocytes. Epoxygenase inhibition was
accompanied by a threefold increase in monocyte numbers
during the 24- to 48-h period of inhibition and a small but
significant increase in PMNs (Fig. 3A). These epoxI-recruited
monocytes were strongly GR1+ (Ly6c and Ly6g antigens; Fig.
3B), and Ly6chi expression was confirmed by RT-PCR (Fig.
3C). Moreover, these recruited cells were CCR2hi (Fig. 3D),
CX3CR1lo (Fig. 3E), and CCL2hi (Fig. 3F) at the mRNA level.
CCL2 peptide was found to be highly elevated in the peritoneal
cavity of epoxI-treated mice (vehicle 8 ± 8 pg/mL; epoxI 266 ±
190 pg/mL CCL2; n = 3). Substantial levels of CCL2 were
produced exclusively from cells elicited from epoxI-treated
mice ex vivo (Fig. 3G), suggesting they could be a major source
of this elevated CCL2. EETs are too short-lived to be given as a
bolus dose in vivo, and therefore to test whether EETs were
antiinflammatory in mouse monocytes, we added back authentic
14,15-EET (1 μM; 7 h) to zymosan-elicited cells ex vivo. 14,15-EET
Fig. 2. Epoxygenase products form in a biphasic manner mirroring acute
inflammation and inflammatory resolution: selective inhibition of CYP-AA
and CYP-LA products by epoxI. (A and B) Mean fold change in (A) CYP-AA
products: DHETs and (B) CYP-LA (DiHOME), CYP-DHA (DiHDPA), and CYP-
EPA (DHEQ) products, 0–48 h. Each mediator was normalized to its paired
levels found in the naive cavity in each experiment; the levels found in the
naive cavity were given an arbitrary value of 1. *P < 0.05 by one-sample t
test from 0 h. †P < 0.05 by unpaired t test between the values observed at 24
and 48 h. (C) Mean fold-change in epoxygenase product formation in the
presence or absence of epoxI (30 mg/kg). EpoxI was given at 24 and 36 h.
Epoxy-oxylipins were measured at 48 h and are represented as fold change
from the respective mean levels observed in the naive cavity at 0 h. *P < 0.05
by unpaired t test. Data represents mean ± SEM.
Table 1. Expression of mouse Cyp2s in the resolving peritoneal
cavity of mice
Cyp Liver Exudate
Cyp2j5 + +/−
Cyp2j6 + ++
Cyp2j9 +/− +
Cyp2j13 Not tested +/−
Cyp2c29 + −
Cyp2c37 ND ND
Cyp2c38 + −
Cyp2c39 − −
Cyp2c40 ND ND
Cyp2c44 +++ ++
Cyp2c50 ++ −
Cyp2c54 ++ −
Cyp2c55 + −
Cyp2a1 +++ −
Cyp2u1 ND +
Cyp2s1 ND +
Mice were treated with zymosan (1 mg, i.p.) for 24 h. The presence of
mouse CYP2 mRNAs was determined by RT-PCR, using mouse liver as a positive
control. The data summarize the findings from n = 6–8 mice. The number of +
signs indicates the relative expression level; +/− indicates that not all samples
tested showed positive expression. ND, not detected.
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reduced Ccl2 (Fig. 3H), inducible nitric oxide synthase (iNOS)
(Fig. 3I), and IL-12 (Fig. 3J) mRNA expression in these cells ex
vivo. Addition of 14,15-EET was not universally antiinflammatory
in these elicited cells, as TNFα mRNA expression remained unal-
tered (Fig. 3H). These results are consistent with our previous
findings, which reported an antiinflammatory role of epox-
ygenases in classically activated human monocytes and
macrophages in vitro (21).
sEH−/− Mice Have an Opposing Phenotype to Epoxygenase-Inhibited
Mice During Resolution. To confirm the role of epoxy-oxylipins
during resolution, we compared the findings of epoxI-treated
mice with sEH−/− mice. sEH is considered the main pathway for
epoxy-oxylipin metabolism and inactivation. Compared with
epoxI-treated mice, which have reduced epoxy-oxylipins, sEH−/−
mice have elevated oxylipins (31). In zymosan-treated mice,
Ly6chi monocytes peaked at 48 h with epoxI treatment (SI Ap-
pendix, Fig. S3), whereas at 48 h in sEH−/− mice, Ly6chi mono-
cytes were reduced compared with wild-type controls (Fig. 4A).
There was a small increase in Ly6g+ cells at 48 h with epoxI,
whereas in sEH−/− mice, Ly6g+ monocytes were slightly reduced
compared with wild-type controls (Fig. 4B). With epoxI treatment,
although there was no change in numbers of macrophage (F4/80)-
positive cells (5.4 ± 0.5 compared with 5.9 ± 2.2 cells per milliliter,
×106), there was a reduction in the levels of F4/80 expression on
the epoxI-elicited macrophages (Fig. 4C). In corollary, the oppo-
site was found in sEH−/−mice: CD11b++ F480++ cells were greatly
elevated compared with wild-type controls (Fig. 4C). CD19+ B
cells (Fig. 4D) and CD3+ T cells (Fig. 4E) were reduced by epoxI
and elevated in sEH−/− mice. There was also a similar trend to
reduction of MHCII+ CD11c+ dendritic cells by epoxI, with a
significant elevation of these MHCII+ CD11c+ dendritic cells
in sEH−/− mice. Therefore, in all of the major indices of in-
flammatory cell accumulation tested, epoxy-oxylipin inhibition
with epoxI showed opposing actions to epoxy-oxylipin elevation
with the use of global sEH−/−.
Cells of the Monocyte Lineage Have a Disrupted Resolution Phenotype
Following Epoxygenase Inhibition. Using a recently identified novel
panel of quantitative (q)RT-PCR of resolution monocyte markers
(32), we examined the total inflammatory cell population for a
changes in the resolution phenotype. The total epoxI-elicited cell
population was Timd4lo, Tgfb2lo, and Plxdc2lo and IL1f9hi, CD86hi,
and Ms4a7hi compared with cells from animals treated with vehicle/
zymosan alone (SI Appendix, Fig. S4). At indicated time points
there was also a significant difference in Ccnb2 (increased with
epoxI) and Aspa and Stfa2l1 (decreased with epoxI) (SI Ap-
pendix, Fig. S4). Because epoxy-oxylipins appear to have the most
dramatic effect on monocyte lineage cell recruitment, we exam-
ined these targets in FACS-sorted Ly6chi and Ly6clo monocyte
populations, resident macrophages, and recruited dendritic cells
(DCs) (Fig. 5). Normal-resolution Ly6chi monocytes were Plxcd2hi,
Aspahi, and F5hi; Ly6clo monocytes were Ccnb2hi, Timd4hi, and
Stfa2l1hi; resident macrophages were IL1F9hi; and dendritic cells
Fig. 3. Epoxygenase inhibition during resolution causes Ly6chi monocyte recruitment and Ccl2 generation. (A) Change in lymphocytes, monocytes/macro-
phages, and PMNs in the peritoneal cavity of mice 48 h postzymosan treatment. At 24 and 36 h, mice were given either sterile PBS or epoxI (30 mg/kg, i.p.).
Total cell numbers were counted on a hemocytometer and the proportion of each cell type was determined by FACS. Data represent the mean ± SEM from
n = 6 mice per group; *P < 0.05 by unpaired t test between vehicle (Cont; PBS) and epoxI-treated mice. (B) Example of FACS analysis of total cell (Upper) and
GR+ populations (Lower) of cells elicited by zymosan alone (control; Left) or in the presence of epoxI (Right) in terms of size (FSc) and granularity (SSc). (C–F)
Relative expression of Ly6c (C), Ccr2 (D), CX3CR1 (E), and CCL2 (F) mRNA compared with β-actin in elicited cells from zymosan + control or epoxI-treated mice
taken at 48 h. (G) CCL2 generation in cells from zymosan + control or epoxI-treated mice. Cells were elicited at 36 h and left for a further 8 h ex vivo and CCL2
was measured by ELISA. (H–K) CCL2 (H), iNOS (I), IL-12 (J), and TNFα (K) mRNA expression in zymosan-elicited cells at 36 h treated with 14,15-EET or 11,12-EET.
Cells were elicited at 36 h and treated for a further 7 h with EETs. Data represent the mean ± SEM from n = 3–4 mice per group; *P < 0.05 by unpaired t test
between vehicle (Cont; PBS) and epoxI-treated mice.
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were Ccr2hi and IL1F9hi (Fig. 5). Treatment with epoxI caused a
significant down-regulation of Plxcd2 in Ly6chi monocytes and
DCs; Ccna2 in Ly6chi and Ly6clo monocytes, resident macro-
phages, and DCs; Ccnb2 in Ly6clo monocytes and DCs; Aspa in
Ly6chi and Ly6clo monocytes; F5 in Ly6chi, resident macro-
phages, and DCs; Tgfb2 in Ly6chi and Ly6clo monocytes, resident
macrophages, and DCs; and Timd4 in Ly6clo monocytes, resident
macrophages, and DCs (Fig. 5A). Treatment with epoxI caused an
up-regulation of Ccr2 in Ly6clo monocytes, resident macrophages,
and DCs; Ccl2 in Ly6chi monocytes, resident macrophages, and DCs;
Ms4A7 in Ly6chi monocytes, resident macrophages, and DCs; CD86
in Ly6clo monocytes and DCs; and IL1F9 in Ly6chi and Ly6clo
monocytes (Fig. 5B). However, Stfa2l1 was up-regulated in Ly6chi
and resident macrophages but inhibited in Ly6clo monocytes. These
findings collectively point toward a more inflammatory phenotype
accompanying epoxygenase inhibition, with a clear induction in either
or both Ccl2 and Ccr2 in all of the cell types and a decrease in
resolution monocyte markers of apoptosis and repair (Timd4 and
Tgfb2, respectively).
Epoxygenase Inhibition Disrupts Resolution-Phase Macrophage
Differentiation and Leads to Impaired Phagocytosis and Efferocytosis.
To examine functional changes in the monocyte lineage, we ex-
amined Ly6c+ monocytes, resident macrophages, and monocyte-
derived macrophage populations. As previously shown, Ly6c+
monocytes were elevated, monocyte-derived macrophages were
reduced, and resident macrophage levels remained unchanged
(Fig. 6). Resident macrophages on a cell-per-cell level showed
reduced expression of differentiation markers and phagocytosis
receptors F4/80, CD11b, MerTk, Timd4, and CD103 but an in-
crease in CD64 (Fig. 6C). A similar reduction in F4/80, MerTK,
Timd4, and CD103 was also observed in monocyte-derived
macrophages (Fig. 6C). In contrast, Ly6c+ monocytes demon-
strated a small but significant increase in markers of differenti-
ation CD11b, Timd4, and CD64, which was again accompanied
by a decrease in CD103 (Fig. 6C).
Using the ImageStream system, we were easily able to identify
phagocytosis from particles and bodies sticking to cells (Fig. 7A).
Ly6c+ monocytes had a small but significant decrease in the ability
to phagocytose zymosan, but not apoptotic cells (Fig. 7B). In con-
trast, resident macrophages and monocyte-derived macrophages
(Fig. 7B) both showed greatly reduced ability to phagocytose FITC-
labeled zymosan A and efferocytose apoptotic cells ex vivo.
Discussion
Our findings show that epoxy-oxylipin–generating pathways
constitute an important control point limiting the accumulation
of proinflammatory Ly6chi monocytes and the proinflammatory
and clearance activity of cells of the monocyte lineage during
inflammatory resolution (Fig. 8). Similar to cyclooxygenases and
lipoxygenases, the epoxygenase pathways of arachidonic acid
metabolism (SI Appendix, Fig. S5) are activated during both
acute inflammation and resolution. There has been great recent
interest in the therapeutic potential of sEH inhibitors as novel
antiinflammatories. sEH inhibitors or genetic disruption of sEH
in mice reduces inflammation in models of endotoxin-induced
pulmonary inflammation (22), ischemia-reperfusion injury (33,
34), subarachnoid hemorrhage (35), and the murine ovalbumin
model of asthma (36), and in more chronic models including
atherogenic diet-induced fatty liver disease and adipose tissue
(37) and atherosclerosis (38, 39). In contrast, the expression and
roles of epoxy-oxylipins during inflammatory resolution have not
been investigated.
Fig. 4. Endogenous oxylipins regulate Ly6chi monocyte, F4/80 macrophage, and CD19 and CD3 cell populations during resolution. Changes in (A) Ly6chi cell
populations, (B) Ly6g+ cell populations, (C) F4/80 expression (mean fluorescence intensity; MFI) (Left) and F4/80++ cell populations (Right), and (D) CD19+, (E)
CD3+, and (F) MHCII+ CD11c+ dendritic cell populations in control and epoxI-treated mice (solid black bars; Left) and in wild-type (wt) and sEH−/−mice (Right).
The proportion of cells in each group was determined by FACS and related back to cell numbers. Data represent the mean ± SEM from n = 4–5 mice per
experimental group; *P < 0.05 by two-way ANOVA or unpaired t test.
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Human monocytes in vitro express CYP2J and CYP2C enzymes,
and in particular CYP2J2 can be induced by TLR4/LPS activation
(21). Rodents have expanded CYP2J and CYP2C subfamilies
compared with humans, and we found the epoxygenase CYP2C44
(40) along with CYP2J6 and CYP2J9 to be present in all in-
flammatory exudates tested, although these findings do not rule
out contributions from other local stromal or vascular cells. To test
the role of epoxygenases, we used the epoxI SKF525A, which we
routinely use in our in vitro assays (18–21, 41) and found to have an
IC50 for human CYP2J2 of 1 μM (20). SKF525A is routinely used
in vivo within the range of 5–50 mg/kg (42–45) and, although
reported as a selective epoxygenase inhibitor, SKF525A had not
been examined in the in vivo setting followed by lipidomic analysis
to confirm this. We chose SKF525A as our epoxI because it is
soluble in aqueous solutions (in our case PBS), and so could be
tolerated far better over longer periods with limited vehicle effect.
In our experiments only epoxygenase products and not prostanoids
or lipoxygenase products were inhibited (by ∼50%) with 30 mg/kg
of epoxI (SI Appendix, Table S1). epoxI was given at 24 h to look at
resolution specifically, so the true levels of inhibition may be
higher, as the kinetics of preformed metabolite removal in the
cavity over the 24- to 48-h time period is not known.
The combination of these experiments using epoxI and sEH−/−
mice leads to the conclusion that epoxy-oxylipins are produced
during resolution by resident and incoming inflammatory cells
and act in a paracrine/autocrine manner to limit Ly6chi monocyte
accumulation and monocyte macrophage proinflammatory phe-
notype. Following epoxI treatment at the onset of resolution, the
elicited cells were predominantly GR1+, Ly6chi, and CX3CR1lo
and produced large amounts of the major Ly6chi chemokine
CCL2. CCL2 was undetectable from cells elicited by zymosan
alone. Interestingly, although limiting Ly6chi monocyte re-
cruitment, epoxy-oxylipins promoted the differentiation of
monocytes into F4/80++ macrophages. In vitro, we previously
found that epoxygenases and 11,12-EET promote macrophage
bacterial phagocytosis, which was associated with a reduction in
CD11b (41). Similarly, here resident and monocyte-derived mac-
rophages had reduced CD11b, along with markers of the mature
macrophage phenotype and phagocytosis MerTK and Timd4, the
latter being particularly important for efferocytosis (46). These
markers correlated with both resident and monocyte-derived
macrophages from epoxI-treated mice to have a dramatic re-
duction in the ability to phagocytose fresh zymosan and effer-
ocytose apoptotic cells. LyC6+monocytes had small but significantly
Fig. 5. Epoxygenase inhibition alters the resolution phenotype of recruited cells of the monocyte lineage. Inflammation was initiated by zymosan (1 mg,
i.p.), and mice were treated with vehicle control (PBS) or epoxI (30 mg/kg, i.p.) at 24 and 36 h. Cells were collected and pooled from n = 10 mice and Ly6chi,
Ly6clo monocytes, resident macrophages, and recruited dendritic cells were sorted on a FACSAria as detailed inMaterials and Methods. A qRT-PCR resolution
monocyte panel (n = 3–6) was then used to examine the phenotype of each cell type. (A–C) In the presence of epoxI, (A) Plxcd2, Ccna2, Ccnb2, Aspa, F5, Tgfb2,
and Timd4 were found to be down-regulated in the cell types; (B) Ccr2, CCL2, Ms4A7, CD86, and IL1F9 were up-regulated in the cell types; and (C) Stfa2l1 was
up- and down-regulated in a cell type-specific manner. *P < 0.05 by unpaired t test. (D, Upper) Summary of the relative basal levels of each transcript in each
cell type. (D, Lower) Summary of the effect of epoxI on the different transcripts. Data represents mean ± SEM.
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elevated CD11b and CD64 expression but reduced CD103. There
was, however, little change in the ability of monocytes to phagocy-
tose material apart from a small reduction in the ability to phago-
cytose zymosan ex vivo. These findings suggest epoxy-oxylipins not
only limit the recruitment of proinflammatory monocytes but also
limit resident and monocyte-derived macrophages’ ability to clear
inflammatory stimuli and apoptotic cells, further indicating a
prominent role for epoxygenase pathways in promoting the res-
olution phenotype. Interestingly, CD19+ B cells and CD3+ T cells
were also increased in sEH−/− mice (and reduced with epoxI
treatment). Lymphocytes are dispensable for resolution in this
model (47) but form an important part of a defense mechanism
against reinfection (47). Although we have yet to investigate fully
which lymphocyte subtypes are present, these findings nonetheless
also provide the first evidence, to our knowledge, for a role for
epoxy-oxylipins in acquired immune responses along with the roles
in resolution reported here.
These findings all point to a proresolution role for epoxy-
oxylipins in the proinflammatory monocyte lineage. CCL2 is
known to be a central mediator of monocyte recruitment. EpoxI-
treated animals produced large amounts of CCL2, as did the
inflammatory cell population taken ex vivo. When we examined
individual cell types, CCL2 was induced by epoxI in Ly6chi
monocytes, resident macrophages, and DCs, whereas its receptor
CCR2 (already expressed in Ly6chi monocytes) was also induced
in Ly6clo monocytes, resident macrophages, and DCs. Using
gene array analysis, we previously identified a panel of novel
resolution monocyte markers (32) including the T-cell cos-
timulator CD86, IL-1 family gene 9 (IL-1f9; IL-36), and CD20-
like family member Ms4a7; these were all elevated after epoxI
treatment, whereas the phosphatidylserine apoptotic cell receptors
Timd4, Tgfb2, and Plxdc2 were all decreased. The roles of a
number of these novel markers are still not known in resolution,
but clearly epoxI-mediated changes in expression along with
changes to functional clear antigens and apoptotic cells represent
cells of a phenotype of highly dysregulated resolution compared
with the typical resolution monocyte cell population.
Recently, the major rat monocyte epoxygenase Cyp2j4 was
knocked out using a zinc finger nuclease-mediated gene-target-
ing approach (48). The resultant bone marrow-derived macro-
phages showed a highly profibrotic enriched transcriptome and
activity and an induction of PPARγ (48). Although not an
identical phenotype to those observed in our study, this adds to
the literature showing that lipid-metabolizing CYPs have a crit-
ical role to play in the inflammatory phenotype of cells in the
monocyte lineage.
EETs are too unstable to give as a bolus dose in vivo. There-
fore, we tested the direct antiinflammatory effects of monocyte
Fig. 6. Epoxygenase inhibition regulates monocyte and macrophage differentiation. Inflammation was initiated by zymosan (1 mg, i.p.), and mice were
treated with vehicle control (PBS) or epoxI (30 mg/kg, i.p.) at 24 and 36 h. Cells were collected at 48 h and pooled from n = 9–18 mice. Ly6c+ monocytes,
resident macrophages, and monocyte-derived macrophages were sorted on a LSR Fortessa as detailed in Materials and Methods. (A) Representative zebra
plots of the cell populations from control and epoxI-treated mice expressing Ly6c and F4/80, with labeled populations representing A: Ly6c+ monocytes; B:
resident macrophages (Resi-Mϕ); and C: monocyte-derived macrophages (Mono-Mϕ). (B) Representative dot plots of the Ly6c+ monocytes, resident macro-
phages, and monocyte-derived macrophages from control and epoxI-treated mice expressing PKH26 and CD11b (Upper) and CD64 and MerTK (Lower). (C)
Changes in cell numbers, and expression (MFI in relative fluorescence units; RFUs) for F4/80, CD11b, MHCII, CD103, CD64,MerTK, and Timd4 in the Ly6c+, Resi-Mϕ,
and Mono-Mϕ cell populations. Data are mean ± SEM from n = 5 mice per group; *P < 0.05 by unpaired t test.
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epoxygenases ex vivo. 14,15-EET, the most abundant epox-
ygenase-derived EET produced in the peritoneal cavity, inhibited
inflammatory cell activation of iNOS and IL-12 ex vivo from
zymosan-treated mice. Interestingly, the linoleic acid epoxygenase
products 9,10-EpOME and 12,13-EpOME are highly expressed in
the naive cavity. The levels of 9,10-EpOME drop rapidly during
acute inflammation, whereas 12,13-EPOME changes very little.
Our results therefore indicate a change in substrate availability
or utilization by epoxygenases from linoleic acid in homeostasis
to arachidonic acid during inflammation. Linoleic acid epox-
ygenase products are generally considered proinflammatory
and cytotoxic (49–51), whereas EETs are antiinflammatory.
How this concept fits with the high levels of EpOMEs and
DiHOMEs in the naive peritoneal cavity is intriguing, and
points to novel as yet undiscovered homeostatic roles for these
mediators in the peritoneal cavity. In contrast to EETs, which
inhibited Ccl2 in monocytes ex vivo, 9,10-EpOME induced
CCL2 (SI Appendix, Fig. S6), suggesting that substrate utiliza-
tion may be an additional layer of control over the effects of the
epoxygenase pathway. High EpOME levels have been found in
acute respiratory distress syndrome and in patients with extensive
burns (52); however, the roles of EpOMEs in inflammation and
homeostasis remain relatively poorly understood, although it is
becoming clearer that many of the cytotoxic effects attributed to
them are in fact due to their sEH metabolite DiHOMEs (51, 53–
55). Clearly more work is needed to elucidate the function of
these linoleic acid epoxygenase products in homeostasis as well as
pathophysiology. At this stage, we cannot rule out potential effects
of DHA and EPA CYP metabolites but, because we saw no sig-
nificant change in their production with epoxI, we have here fo-
cused on arachidonic acid and linoleic acid epoxy-oxylipins.
The levels of 12/15-lipoxygenase, 9,10- and 12,13-HODE, and
12- and 15-HETE were high in the peritoneal cavity, consistent
with the report that high levels of resident macrophages contain
12/15-lipoxygenase in mice, where it regulates immune function.
Our findings are also consistent with this report in that 12/15-
lipoxygenase products drop during acute inflammation (in our
experiments only 9-HODE returned to basal levels by 48 h), and
support the findings that 12/15-lipoxygenase has an important
homeostatic immunoregulatory role in this model (56).
In conclusion, we have characterized the epoxygenase path-
ways during a model of inflammatory resolution. Inhibition of
epoxygenases during this resolution phase established a proin-
flammatory environment that allows the recruitment of proin-
flammatory Ly6c monocytes and macrophages with a highly
dysregulated resolution/clearance phenotype, whereas mice
where epoxygenase products are elevated have an enhanced
resolution phenotype. An efficient and active epoxygenase
pathway therefore joins similar proresolution lipid pathways
such as the resolvins in the requirement for effective inflammatory
resolution. Drugs that elevate epoxygenase products or epox-
ygenase product mimetics therefore represent novel resolution
targets for chronic inflammatory disorders.
Materials and Methods
Materials. EETs were purchased from Cayman Chemical (Cambridge Bio-
science). SKF525A was purchased from Biomol (Affiniti Research Products).
Cytokines and the MCP-1 ELISA were obtained from R&D Systems. The TNFα
ELISA was from eBioscience. Unless otherwise stated, all other reagents were
purchased from Sigma-Aldrich.
Fig. 7. Epoxygenase inhibition reduces the phagocytic activity of monocyte-
derived and resident macrophages. Inflammation was initiated by zymosan
(1 mg, i.p.), and mice were treated with vehicle control (PBS) or epoxI (30 mg/kg,
i.p.) at 24 and 36 h. Cells were collected at 48 h and pooled from n = 9–18 mice.
Ly6c+ monocytes, resident macrophages, and monocyte-derived macrophages
were sorted on a FACSAria as detailed in Materials and Methods. Sorted cells
were then tested for their ability to phagocytose CFSE-labeled apoptotic cells
(thymocytes) or FITC-labeled zymosan BioParticles over 30 min. Cells were gated
using F4/80 or Ly6c on an ImageStreamX Mark II. (A) ImageStream analysis dif-
ferentiates cells that phagocytose apoptotic cells or zymosan (internalization
score >0) from those where particles or bodies just stick to the cell (in-
ternalization score 0). (B) Ex vivo phagocytosis of apoptotic cells (Left) and zy-
mosan (Right) by Ly6c+, Resi-Mϕ, and Mono-Mϕ cell populations from control
and epoxI-treated mice. Data are mean ± SEM from n = 3–6 pooled samples;
*P < 0.05 by unpaired t test.
Fig. 8. Role of epoxy-oxylipins in the resolution phenotype. The resolution
of zymosan-initiated inflammation involves monocytes, dendritic cells, and
T- and B-cell recruitment and the differentiation of monocytes into resolu-
tion-type macrophages. In this process (as revealed by epoxI treatment and
sEH−/−mice), epoxy-oxylipins, most likely EETs, limit Ccl2 and Ccr2 expression,
Ly6chi monocyte accumulation, and T- and B-cell recruitment and encourage
the formation of mature phagocytic resolution macrophages. Ly6chi mono-
cytes, Ly6clo monocytes, dendritic cells, and monocyte-derived and resident
macrophages are all activated in the presence of epoxI.
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Animal Models. All experiments were completed with adult male mice on a
pure C57BL/6 background. Control C57BL6/J mice were bred under standard
conditions and maintained in a 12-h light/dark cycle at 22 °C and given food
and tap water ad libitum in accordance with UK Home Office regulations.
Mice with targeted disruption of sEH were rederived and backcrossed onto a
C57BL/6 genetic background for more than 10 generations, as previously
described (31, 52, 57). sEH− /− mice have significantly higher circulating
epoxide:diol ratios compared with wild-type littermates, consistent with
functional sEH disruption (57, 58). Peritonitis was induced by intraperitoneal
injection of 1 mg type A zymosan in 0.5 mL PBS after 30 s of sonication on ice.
Inflammatory cells were retrieved at the time points described in Results by
injecting 2 mL sterile cell dissociation buffer (Life Technologies). Cells were
counted by hemocytometer, and exudates were stored at −80 °C until further
analysis. In some experiments, the epoxI SKF525A (30 mg/kg) or sterile PBS
(0.5 mL vehicle) was given intraperitoneally 24 h after zymosan injection and
at 12-h time points thereafter up until 96 h. These studies received institutional
review board approval for the use of mice from the UK Home Office.
Lipid Analysis. Eicosanoids and other fatty acid metabolites were extracted
from inflammatory exudates by solid-phase extraction and eluted in ethyl
acetate, essentially as described (22); see SI Appendix, Supplemental Meth-
ods for extended methods. Lipids were separated by reverse-phase HPLC on
2-μm, 150-mm, 5-μm Luna C18 columns (Phenomenex) and quantified using
an MDS Sciex API 3000 triple quadrupole mass spectrometer (Applied Bio-
systems) with negative-mode electrospray ionization and multiple-reaction
monitoring, as described (12). The relative response ratios of each analyte
were used to calculate concentrations while correcting for surrogate losses
via quantification relative to internal standards. The sensitivity of analytes
ranged from 0.25 to 25 pg per sample.
FACS Analysis and Cell Sorting. Flow cytometry and cell sorting were done
on LSRII/LSRFortessa and FACSAria (BD Biosciences), respectively. Cells
were incubated with Fc-blocker (AbD Serotec) and fluorescently labeled
antibodies. Data were analyzed with FlowJo 7.0.1 software (Tree Star)
using fluorescence minus one controls as the reference for setting gates.
Antibodies were obtained from BD Biosciences unless stated [F4/80
(eBioscience), CD11b, CD11c, Ly6c, Ly6g, Gr1, CD3 (BioLegend), CD19, CD4,
CD8, CD62l, CD44, MerTK, CD64, CD103, Timd4, and MHCII (eBioscience)]
(59). To identify resident macrophages (59), PKH26-PCLred (0.35 mL, 500 nM;
Sigma) was injected intraperitoneally 2 h before injection of zymosan. In
cell-sorting experiments, monocytes and macrophages were sorted from a
population of CD19− and CD3− cells as either Ly6c+F4/80+ or Ly6c−F4/80+;
see SI Appendix, Fig. S7 for the gating strategy. For identification of Ly6g+
neutrophils and Ly6c+ monocytes, a combination of Gr1 and anti-Ly6c or
anti-Ly6g was also used. Resident macrophages were characterized as
PKHred++, DCs were characterized as PKHred− MHCII+ and CD11c+, Ly6chi
monocytes were characterized as LyC6hi PKHred+ MHCII−, and Ly6clo
monocytes were characterized as Ly6clo PKHred−, as previously described
(59).
Cell Culture ex Vivo. The peritoneal lavage was treated with ACK lysis buffer
(Thermo Fisher Scientific) to remove erythrocytes. After being washed,
peritoneal cells were suspended in DMEM supplemented with 10% (vol/vol)
FBS and 50 μg/mL penicillin/streptomycin. The cells (2 × 106) were seeded on
a 12-well plate and left to adhere for 45 min in a humidified CO2 incubator.
Nonadherent cells were removed by three washes with DMEM. Remaining
adherent cells (∼1 × 106) were incubated in 0.5 mL DMEM in the presence or
absence of 1 μM 14,15-EET or 11,12-EET or vehicle (0.3% EtOH). After 6 h,
cell-free supernatants were removed and cells were lysed using TRIzol
(Invitrogen) for subsequent RNA extraction.
RT-PCR. Cells analyzed by qRT-PCR were lysed and RNA was isolated using
TRIzol. The panel of resolution markers Timd4 (T-cell Ig and mucin domain-
containing 4), Tgfb2, Plxdc2 (plexin domain-containing protein 2), IL1f9
(interleukin 1 family member 9), CD86, Ms4a7 (membrane-spanning four
domains, subfamily A, member 7), Ccna2 (cyclin A2), Ccnb2 (cyclin B2), F5
(coagulation factor V), Aspa (aspartoacylase), and Stfa2l1 (stefin A2-like 1)
were measured by qRT-PCR as previously described (32). Resolution mono-
cytes were previously found to be enriched for cell-cycle/proliferation genes
as well as for Timd4 and Tgfb2, key systems in the termination of leukocyte
trafficking and clearance of inflammatory cells. Ly6c, CX3CR1, Ccl2, Ccr2,
Cyp2j5, Cyp2j6, Cyp2j9, Cyp2j13, Cyp2c29, Cyp2c38, Cyp2c39, Cyp2c44,
Cyp2c50, Cyp2c54, Cyp2c55, Cyp2a1, Cyp2u1, Cyp2s1, and β-actin were
measured by RT-PCR. Primers are detailed in SI Appendix, Supplemental
Methods.
Efferocytosis and Phagocytosis Assays. Apoptotic cells (thymocytes) were
produced from the thymuses of three naive control C57/BL mice killed 24 h
presort. Harvested thymuses were passed through a 70-μm mesh and then
lysed with ACK buffer for 3 min. Cells were washed twice with RPMI 1640
with 100 U/mL penicillin/streptomycin. To induce apoptosis, thymocytes
were resuspended in media at 2 × 106 cells per mL and exposed to UV
radiation (∼300 nm) for 20 min followed by incubation for 16–24 h at 37 °C
with 5% CO2 using a Syngene UV transilluminator. Cells were then washed
with PBS and labeled with 2 μM carboxyfluorescein succinimidyl ester
(CFSE) according to the manufacturer’s protocol (Life Technologies;
CellTrace CFSE).
Sorted cell populations, 2 × 105 cells per well, were plated in 24-well plates
and resuspended in X-VIVO 15 media (Lonza) containing 10% FBS, 2 mM
L-glutamine, and 1× pen-step. Cells were then challenged with apo-
ptotic thymocytes (5:1 monocyte/macrophage) or FITC-labeled zymosan
A BioParticles (Thermo Fisher Scientific) (10 particles:1 monocyte/mac-
rophage) for 30 min at 37 °C and 5% CO2. Phagocytosis was stopped by
placing the plates on ice. Cells were detached using 10 mM EDTA containing
4 mg/mL lignocaine for 20 min. Cells were stained for either F4/80 or Ly6c
(allophycocyanin) for 20 min (see FACS Analysis and Cell Sorting, above)
before being washed twice with PBS containing 2 mM EDTA. Cells were then
fixed using 4% paraformaldehyde in PBS and analyzed on an ImageStreamX
Mark II (Merck Millipore) (SI Appendix, Fig. S8).
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